Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 11/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 2/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.36 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.36 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5973816 | 0.84 | IDO1 (0.34) | TACR1 | |
| SCHEMBL4797160 | 0.80 | TAAR1 (0.50) | CETPALDH1A1TSHR | |
| Bromide SCHEMBL29076666 | 0.79 | TAAR1 (0.49) | CETPALDH1A1TSHR | |
| SCHEMBL5018562 | 0.78 | ALDH1A1 (0.48) | ALDH1A1TSHR | |
| Bromide SCHEMBL29076679 | 0.76 | ALDH1A1 (0.46) | ALDH1A1TSHR | |
| SCHEMBL15626909 | 0.74 | TAAR1 (0.46) | ALDH1A1 | |
| Bromide SCHEMBL28021569 | 0.73 | TAAR1 (0.44) | ALDH1A1 | |
| SCHEMBL12384370 | 0.72 | PTPN1 (0.43) | TACR1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL23124446 | 0.71 | PLA2G1B (0.40) | ALDH1A1 | |
| SCHEMBL5830123 | 0.71 | PLA2G1B (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179137-A1 | PYRIDONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179137-A1 | PYRIDONE COMPOUND | PTGER4, P2RY4, PTGER1 | TACR1 375/4885RXRA 1427/4885RXRB 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.